Javier Olo-Ibarra

Javier Olo-Ibarra

Auto-generated profile, based on publicly available information

Javier Olo-Ibarra

Department of Emergency Medicine, Boston Medical Center, Boston University, Boston, US

Research Focus & Metrics

Academic Career Length

1Year (2026-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
19 June 2026 in Turkish Journal of Gastroenterology
Verified
Journal Article
Open access
VAVictoria Elena Abadi-Ron
Victoria Elena Abadi-Ron
AMAna Marenco
Ana Marenco
NRNatalia Rojas-Amaris
Natalia Rojas-Amaris
FMFernando Munguia
Fernando Munguia
JOJavier Olo-Ibarra
Javier Olo-Ibarra
ABAlan Bonder
Alan Bonder
Primary biliary cholangitis (PBC) and primary sclerosing cholangitis (PSC) are chronic cholestatic liver diseases characterized by bile duct injury that may progress to fibrosis, cirrhosis, liver failure, and malignancy and ultimately require liver transplantation. Although these diseases share several clinical features, they differ substantially in pathogenesis, clinical course, and therapeutic approaches. Ursodeoxycholic acid remains the standard first-line therapy for PBC; patients with an inadequate biochemical response may be treated with second-line agents such as seladelpar, elafibranor, or fibrates. In contrast, no approved therapy has been shown to slow disease progression in PSC. Emerging therapies primarily target symptom and complication management, and overall management focuses on surveillance and timely referral for liver transplantation. This review summarizes current approaches to risk assessment, treatment, symptom management, monitoring, and transplantation decision-making in both conditions. Cite this article as: Abadi-Ron V, Marenco-Flores A, Rojas-Amaris N, et al. Current treatment of primary biliary cholangitis and primary sclerosing cholangitis: A comprehensive review. Turk J Gastroenterol. Published online June 19, 2026. doi: 10.5152/tjg.2026.26267